Jemperli Dosage & Drug Information

Concise Prescribing Info

Contents

Dostarlimab

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

Monotherapy for adult patients w/ recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC) that has progressed on or following prior treatment w/ platinum-containing regimen. In combination w/ carboplatin & paclitaxel for adult patients w/ dMMR/MSI-H primary advanced or recurrent EC & who are candidates for systemic therapy.

Dosage/Direction for Use

IV Adult Monotherapy 500 mg infusion over 30 min every 3 wk for 4 cycles followed by 1,000 mg every 6 wk for all cycles thereafter. In combination w/ carboplatin & paclitaxel 500 mg infusion over 30 min every 3 wk for 6 cycles followed by 1,000 mg every 6 wk for all cycles thereafter.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01FF07 - dostarlimab ; Belongs to the class of PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Jemperli conc for soln for infusion 500 mg/10 mL

Packing/Price

1's

Jemperli

dostarlimab

Manufacturer:

Ajinomoto Althea